Hansa Biopharma announces positive reimbursement decision for Idefirix[®] (imlifidase) in the Czech Republic
· Idefirix[®] is the first and only product approved for use in highly sensitized patients waiting for a kidney transplant in the Czech Republic[1,2] · Availability of Idefirix[®] for eligible highly sensitized patients to begin January 1, 2023Lund, Sweden, January 2, 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that it has attained reimbursement in the Czech Republic for its first-in-class treatment, Idefirix[®], for the desensitization treatment of highly sensitized adult patients prior to